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Introduction {#s1}
============

Vision impairment represents a serious public health concern since it impacts social, mental, and physical health of an individual. Visual impairment limits independence and activities of daily life. Those with visual impairment require more social support systems, visual aids, and modifications to home life. They are at a higher risk for injuries, falls, psychological conditions, and are admitted to nursing homes earlier compared to those without a vision impairment [@pone.0113779-The1].

Glaucoma is the leading cause of irreversible visual impairment in the world affecting 60.5 million people worldwide in 2010 [@pone.0113779-Quigley1]. In developed countries, half of glaucoma patients may not experience vision loss until the advanced stages of the disease and this is expected to be greater in undeveloped countries [@pone.0113779-Mohammadi1]. Since there is no cure for glaucoma, glaucoma can progress to blindness if left untreated. Further, glaucoma accounts for 12% of blind persons worldwide which is expected to increase to approximately 79.6 million in 2020 [@pone.0113779-Varma1]. The largest impact is expected in China and India, which accounts for 40% of all cases together [@pone.0113779-Varma1].

The burden of the glaucoma has affected both the health care and economic systems. In Canada, alone, vision loss costs the economy \$15.8 billion per year in which 55% is allocated to direct health care costs [@pone.0113779-Canadian1]. Sixty-five per cent of adults with partial or full vision loss are unemployed, which translates to \$4.06 billion annually of lost earnings [@pone.0113779-Canadian1]. The direct costs of glaucoma is estimated in the United States to be \$623 for mild, \$1915 for moderate, and \$2511 for severe forms of glaucoma and similarly in Europe the costs are €455 per person each year for mild glaucoma and €969 per person each year for severe glaucoma [@pone.0113779-Varma1]. Varma et al. reported as glaucoma progresses to each stage, there is an €86 increase in treatments costs in European.

Glaucoma screening is important to detect, diagnose, and treat patients at the earlier stages. Screening and diagnostic tools are significant to prevent glaucoma from progressing to advanced stages and maintaining health vision. In addition, glaucoma prevention will minimize future healthcare costs. Screening improves efficiency of the health care system by increasing the number of patients accessing ophthalmic services and it reduces the number of false-positive referrals to ophthalmologists [@pone.0113779-Shahid1].

The standard of care for glaucoma screening is routine optometrist visits every 2--3 years and any suspect glaucoma patient will be referred to an ophthalmologist for additional diagnostic testing [@pone.0113779-Canadian1]. Those of older ages are at a greater risk of glaucoma and thus ophthalmologists recommend routine optometrist visits every 2 to 4 years for adults between 40 to 64 years and every 1 to 2 years when aged 65 and older [@pone.0113779-Hatt1]. Patients regularly seen by ophthalmologist for other ocular conditions may also be referred for glaucoma diagnostic testing if signs appear. In-patient care for glaucoma (passive "in-person screening") is performed at specialized clinics and includes detailed history, slit lamp examination, visual field testing, and fundus photography performed by the optical technician followed by consultation with the ophthalmologist [@pone.0113779-Glaucoma1].

Teleglaucoma is a relatively new screening and diagnostic tool for targeting remote or under-serviced communities. It uses stereoscopic digital imaging to take ocular images which are transmitted electronically to an ocular specialist. The ocular specialist will then assess the images, identify risk factors and diagnose for glaucoma. If necessary the ocular specialist will refer identified glaucoma cases for medical consultations or to ophthalmologists for follow-up treatment. Unlike other teleophthalmology tools, teleglaucoma requires more sophisticated diagnostic tests. The main tests are optic nerve photographs, Optical Coherence Tomography (OCT), Intraocular Pressure (IOP) measurements, central corneal thickness (CCT) measurements, and visual field tests [@pone.0113779-Kassam1]. The combination of examinations and equipment required can vary based on organizational resources, target goals and populations. However, the more diagnostic tools used during screening for glaucoma the greater the accuracy and effectiveness of the screening process. The equipment required for teleglaucoma are the ophthalmic examination equipment, cameras, and computer imaging software. The A full list of the standard equipment and components of teleglaucoma can be found in [Table 1](#pone-0113779-t001){ref-type="table"} [@pone.0113779-Kassam1].
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###### Standardized teleglaucoma equipment.
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  Components                                                                 Requirements
  ------------------------ ----------------------------------------------------------------------------------------------------------------
  Human Resources           Staff: graders, Ophthalmic technicians, nurses, optometrist, physicians, glaucoma specialists/ophthalmologists
  Information Technology                                        Secure Diagnostic Imaging (SDI) system
                                                                     Videoconferencing equipment
                                                                    Computer systems and software
                                                                          ISDN installation
  Screening Equipment                                                       Retinal camera
                                                                              Tonometer
                                                             Devices to measure central corneal thickness
                                                  Frequency Doubling Technology (FDT) or Humphrey Visual Field test
                                                                     Optical Coherence Tomography
                                                                              Slit lamp
                                                                              Gonioscope
                                                                            Retinal camera
                                                                              Tonometer
                                                             Devices to measure central corneal thickness
  Examinations                                                         Medical & family history
                                                                            Visual acuity
                                                                                 IOP
                                                                                 CCT
                                        Pupil equal and reactive to light (PERL) or relative afferent pupillary defect (RAPD)
                                                                              Slit lamp
                                                                              Gonioscopy
                                                                             Visual field
                                                                          Fundus photographs
                                                                                 OCT
                                                                           Ancillary tests

The advantages reported in the literature include convenience, decreased travel time to medical clinics, increased access to specialized care for glaucoma, and decreased patient costs [@pone.0113779-Kassam2], [@pone.0113779-Tuulonen1] The benefits are mainly seen in remote or under-serviced communities such as Aboriginal communities and rural or remote areas where there is limited ocular specialists. Arora et al. reported improved **access time** (time from patient being referred to the date visit is booked) with teleglaucoma versus standard in-person examinations: 45 days for teleglaucoma versus in-person exam which had 88 days [@pone.0113779-Arora1]. Teleglaucoma had reduced **cycle time** (time from registration until patient leaves clinic) of 78 minutes versus in-person exam of 115 minutes [@pone.0113779-Arora1]. The pioneer teleglaucoma study conducted in Finland reported reduced absence from work by 50% with teleglaucoma versus in-person examination, and in addition reduced traveling (97%), costs (92%), and time (92%) [@pone.0113779-Tuulonen1].

The literature suggests teleglaucoma has comparable diagnostic accuracy. Teleglaucoma technology demonstrated moderate agreement in its ability to diagnose glaucoma (Kappa statistic 0.55% (0.48, 0.62)) [@pone.0113779-Kiage1]. When disc damage had Vertical Cup Disc Ratio (VCDR) greater than 0.7 the Frequency Doubling Technology (FDT) had a substantial agreement with ability to diagnose glaucoma (kappa statistic 0.84) [@pone.0113779-Kiage1]. In addition, a study conducted in rural India compared the ability of teleglaucoma to detect glaucoma compared to standard in-clinic examination and found that there was good agreement in detecting glaucoma [@pone.0113779-Gupta1]. For glaucoma the kappa scores were 0.61 with standard screening versus 0.59 for teleglaucoma [@pone.0113779-Gupta1]. In comparison to the in-person slit lamp examination, the positive predictive value was 77.5% for positive teleglaucoma diagnosis and had a negative predictive value of 82.2% for negative teleglaucoma diagnosis [@pone.0113779-Kiage1]. However, a cohort study conducted by the University of Alberta found 24% of teleglaucoma photographs were deemed unreadable from media opacities, patient cooperation, and unsatisfactory photographic techniques [@pone.0113779-Kiage1].

In this study, a systematic review and meta-analysis was conducted on teleglaucoma screening for patients with glaucoma to evaluate the following: the effectiveness of teleglaucoma as a screening device, its diagnostic accuracy, its diagnostic odds ratio, and its cost-effectiveness in comparison to in-person examination. Section 2 will explain the methods, section 3 provides the detailed analysis, and section 4 concludes with a discussion and implications for future research.

Methods {#s2}
=======

Search Strategy {#s2a}
---------------

A search methodology was used to assist in locating both published and unpublished studies. Research databases and conference meeting abstracts were searched for articles published from 1999 to current, and included MEDLINE (OVID and PubMed), Cochrane Library (Wiley), BIOSIS (Thomson-Reuters), CINAHL (EBSCO), Web of Science (Thomson-Reuters), and EMBASE (OVID). The grey literature was explored by searching Dissertations and Theses (ProQuest), the Canadian Health Research Collection (Ebrary), as well as the annual meeting abstracts of the European Society of Ophthalmology, Canadian Society of Ophthalmology (CSO), Association for Research in Vision and Ophthalmology (ARVO), and American Academy of Ophthalmology (AAO). The Conference Proceedings Citation Index was also included as part of the Web of Science search. Hand searches of ARVO\'s *Investigative Ophthalmology & Visual Science* journal and *Canadian Journal of Ophthalmology* associated with CSO were performed. The search strategies employed database specific subject headings and keywords for glaucoma, tele-screening, detection, and their synonyms. Each strategy was structured to accommodate for database and platform specific terminology, and syntax. Supplementary File S1 contains the complete search strategies used for the various databases ([Table S1](#pone.0113779.s001){ref-type="supplementary-material"}). Alerts were set up for each database to receive publication notifications for new related articles.

Inclusion and exclusion criteria {#s2b}
--------------------------------

Articles included were from any country, all in English, published from 1999 to current, and were research articles. The articles included study population that are adults in the general population or populations at risk of glaucoma. The study population included those with or without glaucoma. Articles on teleglaucoma intervention for glaucoma screening were included, both in-comparison to in-person screening and analyzing teleglaucoma on its own. Outcome measures of teleglaucoma articles selected contained efficiency measures, specificity, sensitivity, and its ability to detect glaucoma, as well as patient benefits and cost data. Economic evaluations such as cost-effectiveness analysis and studies with costing data were also included.

The exclusion criteria was articles published prior to 1999 since teleglaucoma is fairly new and to be consistent with the teleglaucoma screening procedure, year 1999 was selected as a cut-off year. Additionally, non-research articles such as methodology papers, editorials, review articles, commentaries, and letters were excluded. Articles on diagnosis or prognosis, genetic screening, and teleophthalmology for ocular conditions other than glaucoma were eliminated.

A total of 11237 articles were retrieved by searching various databases and an additional 526 were retrieved from hand searching and grey literature search which were then imported into EPPI 4.0 reference manager. Based on the inclusion and exclusion criteria, two reviewers independently reviewed all articles. After removing duplicate articles, 8157 articles were included for screening. Articles were screened by title, abstract, and full text in level 1, 2, and 3 screening respectively. After each level of screening, kappa statistics was calculated to measure reviewer\'s agreement. Additionally, if consensus was not reached by the two reviewers\' then a third reviewer intervened to solve disagreements on article eligibility. The agreement between the two reviewers was excellent (kappa  = 0.86). The PRISMA diagram demonstrating the selection process is displayed in [Figure 1](#pone-0113779-g001){ref-type="fig"} ([Table S3](#pone.0113779.s003){ref-type="supplementary-material"}).

![PRISMA diagram.](pone.0113779.g001){#pone-0113779-g001}

Quality Assessment Strategy {#s2c}
---------------------------

Articles were assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines for publication bias, risk of bias, imprecision, inconsistency, and indirectness [@pone.0113779-Guyatt1]--[@pone.0113779-Guyatt6]. Articles were graded as either low, moderate, or high quality of evidence. The results indicated that 17 articles were high quality, 13 were moderate quality, and 15 articles were graded as low quality of evidence. Despite the quality of evidence, all articles were included in the analysis.

Data Extraction Strategy {#s2d}
------------------------

Qualitative and quantitative data necessary for analysis was obtained from each article. Information on study location, design, effect measures (sensitivity and specificity), percentage of glaucoma diagnosed, service times, image quality, visual acuities, ophthalmic characteristics, and costs were collected. One reviewer extracted data using an excel template. Authors were emailed to obtain missing relevant information. All databases were updated with new information from respective authors. Additional current costing data was provided by ophthalmic equipment vendors INNOVA, Topcon, and Ocular Health Network. Costs were converted to 2014 US dollars [@pone.0113779-Bank1]. This research study has no financial relationships, investments, or sponsorship related to the cited commercial vendors.

Data Analysis {#s2e}
-------------

Data was synthesized and analyzed using STATA 13. When studies reported estimates as range or p-value or multiple estimates, mean and standard deviation (SD) were derived. Hierarchical logistic regression was used to determine the pooled estimates of sensitivity and specificity of teleglaucoma and in-person examination. A graphical representation of the summary estimates was presented in a Hierarchical Summary Receiver Operating Characteristic (HSROC) curve with 95% confidence intervals and 95% prediction regions.

The positive/negative likelihood ratios (LR+/LR−) were calculated using bivariate models to generate estimates of the likelihood of a positive/negative test in a glaucoma/non-glaucoma patient. From this result the diagnostic odds ratio (DOR) was calculated to determine the relative diagnostic effectiveness of teleglaucoma. DOR is the ratio of the odds of a positive screen test in a glaucoma case relative to the odds of a negative screen test in a non-glaucoma case [@pone.0113779-Trikalinos1].

Due to the variability of study effectiveness measures, not one article had a complete set of data. Missing data was treated as statistically missing values and not included in the analysis. Only articles with complete data were included in each analysis. Publication bias was assessed using funnel plots.

Results {#s3}
=======

A total of 45 studies were included in this meta-analysis. [Table 2](#pone-0113779-t002){ref-type="table"} and [Table 3](#pone-0113779-t003){ref-type="table"} display the baseline characteristics of each study. Studies were conducted in fourteen different countries with representation in each continent. All articles were published between 1999 and 2014. The cumulated individuals of all studies were 101,512 participants. All studies were observational studies, as there were no randomized controlled trials conducted. Three studies contained economic evaluations or cost-effectiveness analysis. Of the 45 studies, 16 compared teleglaucoma to in-person examination. The other 29 studies analyzed teleglaucoma without comparison or was an evaluation of different teleglaucoma equipment. There was minimal variation in study populations; they included either glaucoma patients or patients who were at risk of glaucoma (based on diabetes status, family history of glaucoma, age, or ethnicity). [Table 4](#pone-0113779-t004){ref-type="table"} displays additional study details on demographics and study methods (glaucoma definition, pupil dilation, and number of field tests examined). Although there was some variation, less than 10% of studies reported these details. The main outcome measures were specificity and sensitivity ([Table 5](#pone-0113779-t005){ref-type="table"}). Other included outcome measures (percentage of glaucoma diagnosed, referral rate, and proportion of images with poor quality) are displayed in [table 5](#pone-0113779-t005){ref-type="table"}.

10.1371/journal.pone.0113779.t002

###### Baseline characteristics of included studies -- demographics.
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  Author (Year)                                              Location     Study Design   Sample Size                        Population
  ------------------------------------------------------- -------------- -------------- ------------- ------------------------------------------------------
  Tuulonen et al. (1999) [@pone.0113779-Tuulonen1]           Finland           PC            70                         Glaucoma patients
  Eikelboom et al. (1999) [@pone.0113779-Eikelboom1]        Australia          PC            27                         Glaucoma patients
  Li et al. (1999) [@pone.0113779-Li1]                         USA             PC            32                          Diabetic adults
  Yogesan et al. (1999) [@pone.0113779-Yogesan1]            Australia          PC            27           Glaucoma clinic patients/suspected of glaucoma
  Michelson et al. (2000) [@pone.0113779-Michelson1]         Germany           PC            10                    Glaucoma-diagnosed patients
  Yogesan et al. (2000) [@pone.0113779-Yogesan2]            Indonesia          PC            14                     Ophthalmic Clinic patients
  Yogesan et al. (2000) [@pone.0113779-Yogesan3]            Australia          PC            43                     Ophthalmic Clinic patients
  Gonzalez et al. (2001) [@pone.0113779-Gonzalez1]            Spain            PC            139                    Ophthalmic Clinic patients
  Sebastian et al. (2001) [@pone.0113779-Sebastian1]          Spain            CS            74                         Glaucoma suspects
  Wegner et al. (2003) [@pone.0113779-Wegner1]               Germany           PC           1733                            Not stated
  Labiris et al. (2003) [@pone.0113779-Labiris1]              Greece           PC           1205                   Glaucoma-diagnosed patients
  Fansi et al. (2003) [@pone.0113779-Fansi1]                  Canada           PC            33                   Glaucoma suspects or diagnosed
  Jin et al. (2003) [@pone.0113779-Jin1]                      Canada          CEA            339                       Diabetic aboriginals
  Chen et al. (2004) [@pone.0113779-Chen1]                    Taiwan           PC            113                Residents of area aged \>40 years
  de Mul et al. (2004) [@pone.0113779-deMul1]              Netherlands         PC           1729            Optometrist patients at-risk for glaucoma
  Ianchulev et al. (2005) [@pone.0113779-Ianchulev1]           USA             PC            33                   Glaucoma suspects or diagnosed
  Paul et al. (2006) [@pone.0113779-Paul1]                    India            PC            348               Rural residents at risk for glaucoma
  Kumar et al. (2006) [@pone.0113779-Kumar1]                Australia          PC            107                    Patients of the Eye Clinic
  Kumar et al. (2007) [@pone.0113779-Kumar2]               New Zealand         PC            201             General eye examination clinic Patients
  Khouri et al. (2007) [@pone.0113779-Khouri1]              Not Stated         CS            30                    Glaucoma-diagnosed patients
  Pasquale et al. (2007) [@pone.0113779-Pasquale1]             USA             PC            350                             Diabetic
  Khouri et al. (2008) [@pone.0113779-Khouri2]                 USA             PC            28                    Glaucoma-diagnosed patients
  deBont et al. (2008) [@pone.0113779-deBont1]                 USA             PC           1729            Optometrist patients at-risk for glaucoma
  Sogbesan et al. (2010) [@pone.0113779-Sogbesan1]            Canada         CEA/PC          --             Optometrist patients at-risk for glaucoma
  Anton-Lopez et al. (2011) [@pone.0113779-AntonLopez1]       Spain            CS           1599                       At-risk for glaucoma
  Khurana et al. (2011) [@pone.0113779-Khurana1]              India            CS           91698                   Ophthalmic Clinic patients
  Staffieri et al. (2011) [@pone.0113779-Staffieri1]         Tasmania          PC            133       High risk (First degree relatives of diagnosed POAG)
  Swierk et al. (2011) [@pone.0113779-Swierk1]               Germany           EE            --                     Ophthalmic Clinic patients
  Amin et al. (2012) [@pone.0113779-Amin1]                    Canada           PC            72              Glaucoma suspects or early stages of OAG
  Shahid et al. (2012) [@pone.0113779-Shahid1]                 USA             CS            341                   Urban soup kitchen/homeless
  Kassam et al. (2012) [@pone.0113779-Kassam1]                Canada           PC            257           At-risk for glaucoma or early-stage glaucoma
  Gupta et al. (2013) [@pone.0113779-Gupta1]                  India            PC            247                    Ophthalmic Clinic patients
  Damji et al. (2013) [@pone.0113779-Damji1]                  Canada           PC            71                     Ophthalmic Clinic patients
  Kiage et al. (2013) [@pone.0113779-Kiage1]               rural Africa        PC            309                         Diabetic adults
  Verma et al. (2013) [@pone.0113779-Verma1]                  Canada           RC            247       Optometrist-referred glaucoma suspects or early OAG
  Ahmed et al. (2013) [@pone.0113779-Ahmed1]                   USA             RC            643                    Diabetic and hypertensive
  Arora et al. (2014) [@pone.0113779-Arora1]                 Alberta           PC            71           Glaucoma clinic patients/suspected of glaucoma

Legend: CS  =  Cross-Sectional Study, PC  =  Prospective Cohort Study, CEA  =  Cost-effectiveness Analysis, RCS  =  Retrospective Cohort Study, EE  =  Economic Evaluation, --  =  Not Stated.

10.1371/journal.pone.0113779.t003

###### Baseline characteristics of included studies -- intervention.
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  Author (Year)                                                                                         Teleglaucoma Equipment                                                          Comparator
  ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -------------------------------
  Tuulonen et al. (1999) [@pone.0113779-Tuulonen1]                  Canon CR5-45NM non-mydriatic fundus camera, slit-lamp, Panasonic video camera, HF II perimeter                 In-person examination
  Eikelboom et al. (1999) [@pone.0113779-Eikelboom1]                                              Nidek Nm-100 Handheld fundus camera                                                Teleglaucoma only
  Li et al. (1999) [@pone.0113779-Li1]                                                       Non-mydriatic retinal camera. Digital images                                      Image Quality of Teleglaucoma
  Yogesan et al. (1999) [@pone.0113779-Yogesan1]                                                  Portable fundus camera, Nidek NM100                                                Teleglaucoma only
  Michelson et al. (2000) [@pone.0113779-Michelson1]                               Self-tonometry portable device called Ocuton, PalPilot, IOP curve                                 Teleglaucoma only
  Yogesan et al. (2000) [@pone.0113779-Yogesan2]                                                    Handheld fundus camera (NM100)                                                   Teleglaucoma only
  Yogesan et al. (2000) [@pone.0113779-Yogesan3]              DIO digital indirect ophthalmoscope, handheld fundus camera Nidek NM100, stereo fundus camera (Nidek 3D-x)             Teleglaucoma only
  Gonzalez et al. (2001) [@pone.0113779-Gonzalez1]                                            Non-mydriatic fundus camera (canon CR6-45M)                                          In-person examination
  Sebastian et al. (2001) [@pone.0113779-Sebastian1]                               C-20-5 FDT, Humphrey-Zeiss, & Topcon optic nerve head photographs                                 Teleglaucoma only
  Wegner et al. (2003) [@pone.0113779-Wegner1]                                               Goldman applanation tonometer and mobile HRT                                            Teleglaucoma only
  Labiris et al. (2003) [@pone.0113779-Labiris1]                           Slit lamp, Octapus perimeter visual field, fundus camera, Optotype, air tonometer                       In-person examination
  Fansi et al. (2003) [@pone.0113779-Fansi1]                                                                      --                                                             Healthy vs Glaucoma eyes
  Jin et al. (2003) [@pone.0113779-Jin1]                                                                       Tonometry                                                           In-person examination
  Chen et al. (2004) [@pone.0113779-Chen1]                            Digital 35-degree colour fundus images, non-mydriatic digital fundus camera (CR6-45, Canon)                  In-person examination
  de Mul et al. (2004) [@pone.0113779-deMul1]                                                          Nerve fibre analyser, GDx                                                   In-person examination
  Ianchulev et al. (2005) [@pone.0113779-Ianchulev1]                                                      Peristat: self-test                                                      In-person examination
  Paul et al. (2006) [@pone.0113779-Paul1]                                                                        --                                                                 Teleglaucoma only
  Kumar et al. (2006) [@pone.0113779-Kumar1]                                                               I-care tonometry                                                          Teleglaucoma only
  Kumar et al. (2007) [@pone.0113779-Kumar2]                                                                      --                                                               In-person examination
  Khouri et al. (2007) [@pone.0113779-Khouri1]                                                 Digital stereo fundus camera - Nidek 3-Dx                                       Image Quality of Teleglaucoma
  Pasquale et al. (2007) [@pone.0113779-Pasquale1]         Topcon TRC NW-5S non-mydriatic retinal camera (Paramus) interfaced to a standard color video camera (Sony 970-MD)         Teleglaucoma only
  Khouri et al. (2008) [@pone.0113779-Khouri2]                                       Non-mydriatic 45-deg camera, Canon Japan. DICOM image format                              Image Quality of Teleglaucoma
  deBont et al. (2008) [@pone.0113779-deBont1]                                                         Nerve fibre analyser, GDx                                               Image Quality of Teleglaucoma
  Sogbesan (2010) [@pone.0113779-Sogbesan1]                                                                       --                                                               In-person examination
  Anton-Lopez et al. (2011) [@pone.0113779-AntonLopez1]                             HRT, nerve-fibre analyzer (GDX-VCC), I-Care (rebound tonometry)                                In-person examination
  Khurana et al. (2011) [@pone.0113779-Khurana1]                                                                  --                                                                 Teleglaucoma only
  Staffieri et al. (2011) [@pone.0113779-Staffieri1]                                                              --                                                                 Teleglaucoma only
  Swierk et al. (2011) [@pone.0113779-Swierk1]                                                                    --                                                               In-person examination
  Amin et al. (2012) [@pone.0113779-Amin1]                              Slit lamp, IOP, CCT, visual field, anterior and stereo posterior segment photos and OCT                    In-person examination
  Shahid et al. (2012) [@pone.0113779-Shahid1]                                                8.2 megapixel non-mydriatic retinal camera                                             Teleglaucoma only
  Kassam et al. (2012) [@pone.0113779-Kassam1]                                              Remote service - slit lamp, fundus photographs,                                        In-person examination
  Gupta et al. (2013) [@pone.0113779-Gupta1]                                                          Fundus Camera (Portcam II)                                                   In-person examination
  Damji et al. (2013) [@pone.0113779-Damji1]                                                                      --                                                               In-person examination
  Kiage et al. (2013) [@pone.0113779-Kiage1]                                                                  Topcon 777                                                           In-person examination
  Verma et al. (2013) [@pone.0113779-Verma1]                                                                      --                                                               In-person examination
  Ahmed et al. (2013) [@pone.0113779-Ahmed1]                                               Topcon TRC non-mydriatic retinal camera, Tonopen                                          Teleglaucoma only
  Arora et al. (2014) [@pone.0113779-Arora1]                                                                      --                                                               In-person examination

10.1371/journal.pone.0113779.t004

###### Additional Details on Baseline Characteristics of Included Studies.
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  Author (Year)                                                                            Study Population Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                     Glaucoma definition                                                                                                                                                                                                                                                                                                                                                                                     Dilated pupil   \# Field tests
  ------------------------------------------------------- --------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ----------------
  Eikelboom et al. (1999) [@pone.0113779-Eikelboom1]                                                   --                                                                                                                                                                                                                                                                                                                                                                                                                                          --                                                                                                                                                                                                                                                                                                                                                                                                  Yes              --
  Yogesan et al. (1999) [@pone.0113779-Yogesan1]                                                       --                                                                                                                                                                                                                                                                                                                                                                                                                                          --                                                                                                                                                                                                                                                                                                                                                                                                  Yes              --
  Yogesan et al. (2000) [@pone.0113779-Yogesan2]                                                       --                                                                                                                                                                                                                                                                                                                                                                                                                                          --                                                                                                                                                                                                                                                                                                                                                                                                  Yes              --
  Yogesan et al. (2000) [@pone.0113779-Yogesan3]                                                       --                                                                                                                                                                                                                                                                                                                                                                                                                                          --                                                                                                                                                                                                                                                                                                                                                                                                  Yes              --
  Ianchulev et al. (2005) [@pone.0113779-Ianchulev1]                              15% White, 9% African American, 76% Hispanic                                                                                                                                                                                                                                                                                                                                                                                                                     --                                                                                                                                                                                                                                                                                                                                                                                                  No               --
  Chen et al. (2004) [@pone.0113779-Chen1]                                                         100% Asian                                                                                                                                                        "The diagnosis of glaucoma was made according to the anatomical findings from the patient\'s optic nerve disc, and functional visual field examination by frequency-doubling perimetry (FDP). Intraocular pressure (IOP) was also evaluated. An elevated IOP was defined as over 17 mmHg (1 mmH = 133 Pa). Severe glaucoma was defined as an optic cup: disc ratio over 0.7 with an FDP defect or elevated IOP. Mild glaucoma was defined as an optic cup: disc ratio between 0.7 and 0.5, or disc asymmetry of over 20%, with an FDP defect or elevated IOP."                                                                                                                    --               --
  Kumar et al. (2006) [@pone.0113779-Kumar1]                                                 96% Caucasian, 4% Asian                                                                                                                                                                                                                                                                                                                                                                                                      IOP of 21 mmHg was threshold for suspected glaucoma                                                                                                                                                                                                                                                                                                                                                                          --               --
  Paul et al. (2006) [@pone.0113779-Paul1]                                                         100% Indian                                                                                                                                                                                                                                                                                                                                                                                                                                     --                                                                                                                                                                                                                                                                                                                                                                                                  --               --
  Kumar et al. (2007) [@pone.0113779-Kumar2]                                                           --                                                                                                                                                                                                                                                                                                                                         In accordance with glaucoma screening protocol of Lions Eye Institute: Vertical cup disc ratio (VCDR) \>0.5, IOP \>21 mmHg, abnormal visual field related to glaucoma, and or disk asymmetry \>0.2.                                                                                                                                                                                                                                                                                                  Yes              --
  Pasquale et al. (2007) [@pone.0113779-Pasquale1]         16% African American (of glaucoma suspects) 14% African American (Of non-glaucoma suspects)   "VFs were considered glaucomatous if the pattern deviation plot showed a nasal step, nasal depression, arcuate defect, paracentral loss that respected the horizontal meridian, or temporal wedge defects based on previously published criteria... Patients were designated as "no glaucoma" if the CDR was "\<0.6 in both eyes and CDR asymmetry was \<0.1 in the absence of reliable glaucomatous VFs. Patients were designated as having "glaucoma-suspicious optic discs" if the CDR was "\>0.6 in either eye or CDR asymmetry was \>0.1 with or without reliable glaucomatous VFs. Patients with more subtle optic nerve changes were labeled as having glaucoma-suspicious optic discs if VFs were available and reliable and showed change consistent with glaucomatous loss."        --             Three
  Staffieri et al. (2011) [@pone.0113779-Staffieri1]                                                   --                                                                                                                                                                                  "Subjects were classified as having definite glaucoma on the basis of characteristic optic nerve head changes (cup: disc ratio \[CDR\] outside the 97.5 percentile for the normal population or rim width less than 0.1 CDR at the superior and inferior poles of the disc) and definite visual field defect consistent with glaucoma. Individuals with stereoscopic disc photos consistent with structural damage but in whom field testing was unreliable or unobtainable were classified as glaucoma suspect."                                                                                                                                           Yes              --
  Khurana et al. (2011) [@pone.0113779-Khurana1]                                                   100% Indian                                                                                                                                                                                                                                                                                                                                                                                                                                     --                                                                                                                                                                                                                                                                                                                                                                                                  --               --
  Anton-Lopez et al. (2011) [@pone.0113779-AntonLopez1]                                                --                                                                                                                                                                                                                                                                                                                                "2/3 Criteria were considered suspects and referred for glaucoma consultation: (1) global Moorefield\'s Regression Analysis borderline or outside normal limits, (2) Nerve Fibre Index \>30, and tonometry \>21 mmHg."                                                                                                                                                                                                                                                                                        --               --
  Shahid et al. (2012) [@pone.0113779-Shahid1]                           78% African American, 10% Caucasian, 6.7% Hispanic, 4.8% Other                                                                                                                                                                                                                                                                                                                                                                                                            --                                                                                                                                                                                                                                                                                                                                                                                                  Yes             One
  Kiage et al. (2013) [@pone.0113779-Kiage1]                                                      100% African                                                                                   Category 1 diagnosis (structural and functional evidence): 2 out of 3 of the following: VCDR ≥0.7, focal glaucoma disc changes, VCDR asymmetry (≥0.2). Category 2 diagnosis (structural evidence with unproved field loss): 2 out of 3 of the following: VCDR ≥0.8, focal glaucoma disc changes, VCDR asymmetry ≥0.3. Category 3 diagnosis (optic disc not clearly seen): 1 of the following visual acuity \<3/60 and IOP\> 21 mmHg or visual acuity \<3/60 and evidence of glaucoma surgery or medical records confirming glaucoma morbidity. Glaucoma suspect: one of the following IOP ≥23 mmHg, 1/3 of the glaucomatous optic neuropathy listed in category 2, glaucoma visual field defect only.                                                 Yes            Three
  Gupta et al. (2013) [@pone.0113779-Gupta1]                                                       100% Indian                                                                                                                                                                                                                                                                                                                                                                                          Glaucoma diagnosis based on disc findings VCDR of ≥0.7 or focal neuroretinal rim defect.                                                                                                                                                                                                                                                                                                                                                       Yes              --

10.1371/journal.pone.0113779.t005

###### Study relevant outcome measures.
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  Author (Year)                                            Specificity (%)   Sensitivity (%)   Percentage Glaucoma diagnosed   Percentage Referral Rate   Percentage of Image of Poor Quality
  ------------------------------------------------------- ----------------- ----------------- ------------------------------- -------------------------- -------------------------------------
  Li et al. (1999) [@pone.0113779-Li1]                           --                --                       --                            --                             18.8
  Yogesan et al. (1999) [@pone.0113779-Yogesan1]                84.5              82.5                      --                            --                              --
  Eikelboom et al. (1999) [@pone.0113779-Eikelboom1]            71.5               67                       --                            --                              --
  Yogesan et al. (2000) [@pone.0113779-Yogesan3]                 87                100                      --                            --                              --
  Gonzalez et al.(2001) [@pone.0113779-Gonzalez1]                --                --                       7.9                           --                              13
  Sebastian et al. (2001) [@pone.0113779-Sebastian1]             --                --                       2.7                           --                               4
  Wegner et al. (2003) [@pone.0113779-Wegner1]                   --                --                                                     --                              9.4
  de Mul et al. (2004) [@pone.0113779-deMul1]                    58                82                       4.6                           11                              --
  Ianchulev et al. (2005) [@pone.0113779-Ianchulev1]            95.5              81.5                      --                            --                              --
  Kumar et al. (2006) [@pone.0113779-Kumar1]                    98.8              38.1                      --                            --                              --
  Kumar et al. (2007) [@pone.0113779-Kumar2]                    93.6              91.1                      --                            --                              --
  Pasquale et al. (2007) [@pone.0113779-Pasquale1]               96                59                       --                            --                              --
  deBont et al. (2008) [@pone.0113779-deBont1]                   --                --                       --                            11                              11
  Staffieri et al. (2011) [@pone.0113779-Staffieri1]             --                --                        5                            --                              --
  Anton-Lopez et al. (2011) [@pone.0113779-AntonLopez1]          --                --                       1.9                          7.7                              --
  Khurana et al. (2011) [@pone.0113779-Khurana1]                 --                --                      1.06                          12.5                             --
  Shahid et al. (2012) [@pone.0113779-Shahid1]                   --                --                       32                                                            --
  Ahmed et al. (2013) [@pone.0113779-Ahmed1]                     --                --                       --                           19.4                              5
  Gupta et al. (2013) [@pone.0113779-Gupta1]                    81.82             72.1                      --                            --                              --
  Kiage et al. (2013) [@pone.0113779-Kiage1]                    89.6              41.3                      14                            --                              24
  Verma et al. (2013) [@pone.0113779-Verma1]                     --                --                       31                            31             
  Arora et al. (2014) [@pone.0113779-Arora1]                     --                --                       44                            --                              --

Costing data was given by nine studies and the quality of analysis of costing is displayed in [table 6](#pone-0113779-t006){ref-type="table"}. Teleglaucoma costs vary by the capacity of the service and the type and amount of equipment. The current vendor estimate shows that the total costs for standard glaucoma equipment range from 89,703.53 to 123,164.55 US dollars ([Table 6](#pone-0113779-t006){ref-type="table"}) [@pone.0113779-INNOVA1], [@pone.0113779-Topcon1]. Additionally, to transfer images and patient test results securely to ophthalmologists electronically a service exists costing \$62.13 US/month [@pone.0113779-Bank1], [@pone.0113779-Ocular1]. This service allows teleglaucoma technicians and ophthalmologists to login electronically to attach, send, view and assess retinal images and patient test results.

10.1371/journal.pone.0113779.t006

###### Quality of analysis for costing.
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  Author (Year)                                                                                           Object                                      Costs (\$)           Currency
  -------------------------------------------------------------------------- ---------------------------------------------------------------- --------------------------- ----------
  Tuulonen et al. (1999) [@pone.0113779-Tuulonen1]                                                  [Fixed Costs]{.ul}                                                    
                                                                                                  Fundus camera (1 unit)                                  200                FIM
                                                                                               ISDN installation (3 units)                                6.5                FIM
                                                                                          Server computer (2 units for 5 years)                           50                 FIM
                                                                                         Software application (2 units for 5yrs)                          50                 FIM
                                                                                                 Video slit-lamp (1 unit)                                 40                 FIM
                                                                                                 Write off 10 years (3%)                                 40.62               FIM
                                                                                            Use of teleophthalmology equipment                          24.372               FIM
                                                                                                Video conference equipment                                84                 FIM
                                                                                                    Write-off 5 years                                   18.342               FIM
                                                                                             Automated perimetry -- Humphrey                              132                FIM
                                                                                                 Write off 10 years (3%)                                15.474               FIM
                                                                                                 [Other fixed costs]{.ul}                                                 
                                                                                                   Service and updating                                    5                 FIM
                                                                                                   Line costs per month                                  3.672               FIM
                                                                                                         Premise                                         1.608               FIM
                                                                                                        Utilities                                        1.608               FIM
                                                                                                       Other costs                                       7.133               FIM
  Yogesan et al. (2000) [@pone.0113779-Yogesan2]                                                     Satellite phone                                     30000               EUR
                                                                                                       Mobile phone                                      3250                EUR
  Jin et al. (2003) [@pone.0113779-Jin1]                                                        Total expenditure capital                               160260               CAN
                                                                                                Operating costs per 1 year                              348665               CAN
                                                                                                   Projected 2005 Costs                                 385226               CAN
                                                                                          Operating costs amortized over 5 years                         32052               CAN
                                                                                 Operating costs amortized over 5 years per diabetic case                1231                CAN
                                                                                                Professional and Lab Fees                                 291                CAN
                                                                                                    Costs per patient                                    1231                CAN
                                                                                                       Travel costs                                       805                CAN
                                                                                                  Escort travel expenses                                  340                CAN
  Chen et al. (2004) [@pone.0113779-Chen1]                                                       Costs per detected case                                  10                  US
  Ianchulev et al. (2005) [@pone.0113779-Ianchulev1]                                      Costs per targeted glaucoma screening                           60                  US
                                                                                                 Costs per detected case                                 1000                 US
  Sogbesan (2010) [@pone.0113779-Sogbesan1]                                                          Patient savings                                     2527                CAN
  Anton-Lopez et al. (2011) [@pone.0113779-AntonLopez1]                                             Incremental Costs                                    24150               EUR
                                                                                                 Costs per detected case                                 1420                EUR
                                                                                                    Primary Care visit                                    15                 EUR
                                                                                                 General Ophthalmic Visit                                 18                 EUR
                                                                                               Ophthalmic Visit with tests                                52                 EUR
                                                                                                  Glaucoma Consultation                                   26                 EUR
  Swierk et al. (2011) [@pone.0113779-Swierk1]                                                         Medical Care                                     291.21               EUR
                                                                                                   Accommodation costs                                    280                EUR
                                                                                                    Costs per patient                                   288.72               EUR
  Ahmed et al. (2013) [@pone.0113779-Ahmed1]                                  Equipment costs (digital retinal camera, Tonopen and computer)             46000                US
  Vendor Estimates (2014) [@pone.0113779-INNOVA1], [@pone.0113779-Topcon1]                                 OCT                                      48,000--49,000           CAN
                                                                                                        Slit Lamp                                    7,420--19,990           CAN
                                                                                                                                                                          
                                                                                                     [Tonometer]{.ul}                                                     
                                                                                                    Slit lamp mounted                                1,400--2,400            CAN
                                                                                                       Non-contact                                       8,995               CAN
                                                                                                                                                                          
                                                                                                      Retinal Camera                                27,900--27, 995          CAN
                                                                                                  Visual Field Analyser                             16,340--32,420           CAN
                                                                                                     **TOTAL RANGE:**                          **89,703.53--123,164.55**      US
  Ocular Health Network (2014) [@pone.0113779-Ocular1]                                           Imaging Transfer Service                              70/Month              CAN

Costing data from the literature shows the cost per detected case of glaucoma ranged from \$13.03--2020.96 US after conversion to US dollars and adjusted for inflation to 2014 costs ([Table 7](#pone-0113779-t007){ref-type="table"}) [@pone.0113779-Bank2]. The mean cost is \$1098.67 US for every case of glaucoma detected (n = 3) ([Table 7](#pone-0113779-t007){ref-type="table"}). The mean cost of teleglaucoma per patient screened was \$922.77 US (n = 2) ([Table 7](#pone-0113779-t007){ref-type="table"}).

10.1371/journal.pone.0113779.t007

###### Teleglaucoma estimated 2014 unit costs.
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  Author (Year)                                            Cost per detected case (\$US) (Adjusted for inflation to 2014 costs)   Inflation Rate (%)   Cost per patient (\$US) (Adjusted for inflation to 2014 costs)   Inflation Rate (%)
  ------------------------------------------------------- ---------------------------------------------------------------------- -------------------- ---------------------------------------------------------------- --------------------
  Jin et al. (2003) [@pone.0113779-Jin1]                                                    --                                            --                                      1434.63                                     25.49
  Chen et al. (2004) [@pone.0113779-Chen1]                                                13.03                                         30.32                                        --                                         --
  Ianchulev et al. (2005) [@pone.0113779-Ianchulev1]                                     1262.02                                         26.2                                        --                                         --
  Anton-Lopez et al. (2011) [@pone.0113779-AntonLopez1]                                  2020.96                                         5.89                                        --                                         --
  Swierk et al. (2011) [@pone.0113779-Swierk1]                                              --                                            --                                       410.91                                      5.89
  **Mean costs**                                                                       **1098.67**                                                                               **922.77**                            

Another necessary costing aspect is the ophthalmologist fee for glaucoma consultation. The ophthalmologist may be compensated for each teleglaucoma referral or time spent on teleophthalmology consultations. Compensation varies by states and/or provinces, government legislation, and available private grants. In the United States, *Medicare* and *Medicaid* provide several reimbursement programs for physicians delivering telemedicine consultations [@pone.0113779-Centers1], [@pone.0113779-Centers2]. In Ontario, Canada, the compensation for the fee-for service model, is \$16.00 CAN per ophthalmic referral [@pone.0113779-Toronto1]. The physician liable for teleglaucoma consultations must be a licensed ophthalmologist in both the area of the service and the patient. Physicians must hold liability coverage appropriate to state/provincial laws. In Canada, the *Canadian Medical Protective Association* provides ophthalmologists with liability coverage for teleophthalmology [@pone.0113779-Ng1].

Ten studies had complete data necessary to conduct the analysis for teleglaucoma diagnostic accuracy. The summary estimate for sensitivity was 0.833 \[95% CI 0.77, 0.88\] and specificity was 0.79 \[95% CI 0.668, 0.875\] for glaucoma screening using optic nerve examinations ([Figure 2](#pone-0113779-g002){ref-type="fig"}). The summary estimates indicate that teleglaucoma correctly detects 83.3% of glaucoma cases and correctly classifies 79% of those without glaucoma as glaucoma-negative. [Figure 3](#pone-0113779-g003){ref-type="fig"} displays each study estimate and the summary estimate with its associated confidence intervals and the generated HSROC curve. The distribution of the studies in the plot demonstrates the variability of both specificity and sensitivity amongst studies. Six studies fall outside of the 95% confidence interval of the summary estimate. The 95% prediction region is the estimate of future observations. The results demonstrate a fairly wide prediction region for both true predictions of specificity and sensitivity, with greater variability expected for specificity.

![Hierarchical logistic regression results.](pone.0113779.g002){#pone-0113779-g002}

![Hierarchical Summary Receiver Operating Characteristic (HSROC) plot.](pone.0113779.g003){#pone-0113779-g003}

The study populations used to assess diagnostic accuracy were those at-risk of glaucoma (based on diabetes status, family history, age, ethnicity, etc.), optometrist and ophthalmic clinic patients, and patients who were glaucoma suspects ([Table 1](#pone-0113779-t001){ref-type="table"}). One study reported its study population as glaucoma patients only ([Table 1](#pone-0113779-t001){ref-type="table"}) and contrary, this study had one of the lower reported scores for diagnostic accuracy: specificity was 71.5% and sensitivity was 67% ([Table 5](#pone-0113779-t005){ref-type="table"}) [@pone.0113779-Eikelboom1].

The diagnostic tools of the included studies varied slightly ([Table 8](#pone-0113779-t008){ref-type="table"}). Eight out of the ten studies analyzed for sensitivity and specificity used at minimum optic nerve examinations as part of the screening process ([Table 8](#pone-0113779-t008){ref-type="table"}). The other two studies reported using IOP or visual field defects as the methods to detect glaucoma suspects ([Table 8](#pone-0113779-t008){ref-type="table"}). For these studies which did not include fundus photographs, the sensitivity and specificity were 81.5% and 95.5% respectively for glaucoma screening using only visual field and 38.1% and 98.8% respectively for glaucoma screening using IOP and Orbscan Topography ([Table 5](#pone-0113779-t005){ref-type="table"}) [@pone.0113779-Ianchulev1], [@pone.0113779-Kumar1].

10.1371/journal.pone.0113779.t008

###### Study ophthalmic examinations.
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  Author (Year)                                                                                      Examination tests
  ------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Li et al. (1999) [@pone.0113779-Li1]                                                         Optic disc photographs, VCDR
  Yogesan et al. (1999) [@pone.0113779-Yogesan1]                                                           VCDR
  Eikelboom et al. (1999) [@pone.0113779-Eikelboom1]                                                       VCDR
  Yogesan et al. (2000) [@pone.0113779-Yogesan3]                                      Fundus images, H/VCDR, radial rim measurements
  Gonzalez et al.(2001) [@pone.0113779-Gonzalez1]                                                      Fundus images
  Sebastian et al. (2001) [@pone.0113779-Sebastian1]                               Visual acuity, IOP, FDT, optic nerve head photographs
  Wegner et al. (2003) [@pone.0113779-Wegner1]                                                         HRT, IOP, OCT
  de Mul et al. (2004) [@pone.0113779-deMul1]                                                   IOP, nerve fibre indicators
  Ianchulev et al. (2005) [@pone.0113779-Ianchulev1]                                                HVF, visual acuity
  Kumar et al. (2006) [@pone.0113779-Kumar1]                                                           IOP, CCT, ACT
  Kumar et al. (2007) [@pone.0113779-Kumar2]                                 IOP, FDT, VCDR, disc asymmetry, visual field, fundus photographs
  Pasquale et al. (2007) [@pone.0113779-Pasquale1]                            IOP, CDR, Humphrey visual field, comprehensive eye examination
  deBont et al. (2008) [@pone.0113779-deBont1]                                        Nerve fiber indicators, fundus photographs, IOP
  Staffieri et al. (2011) [@pone.0113779-Staffieri1]       Visual acuity, refractive status, visual field testing, IOP, CCT, stereoscopic optic disc photographs
  Anton-Lopez et al. (2011) [@pone.0113779-AntonLopez1]                                      IOP, HRT, nerve fibre indicators
  Khurana et al. (2011) [@pone.0113779-Khurana1]                                                            --
  Shahid et al. (2012) [@pone.0113779-Shahid1]                          IOP, optic nerve head appearance and asymmetry, nerve fibre layer dropouts
  Ahmed et al. (2013) [@pone.0113779-Ahmed1]                                                      Fundus images, CDR, IOP
  Gupta et al. (2013) [@pone.0113779-Gupta1]                                                        Fundus photographs
  Kiage et al. (2013) [@pone.0113779-Kiage1]                    Slit lamp examination, focal glaucoma damage, VCDR, IOP, FDT, fundus images, visual fields
  Verma et al. (2013) [@pone.0113779-Verma1]                        Stereoscopic optic nerve images, visual fields, ancillary tests, IOP, OCT, and HRT
  Arora et al. (2014) [@pone.0113779-Arora1]                                      OCT, HRT, stereo-nerve photographs, FDT, HVF, OCT, IOP

**Legend:** VCDR  =  vertical cup-to-disc ratio, HCDR  =  horizontal cup-to-disc ratio, IOP  =  intraocular pressure, FDT  =  frequency doubling technology, CCT  =  central corneal thickness, HRT  =  Heidelberg Retinal Tomography, CDR  = cup-to-disc ratio, HVF  =  Humphrey Visual Field, ACT  =  anterior chamber depth, POAG  =  primary open angle glaucoma, OAG  =  open angle glaucoma.

Three studies reported sensitivity and specificity of in-person examination. The weighted mean of sensitivity was 74.9±27.6% (n = 3) and specificity was 88.8±10.3% (n = 3) for in-person examination. The summary estimates indicate that in-person examination correctly detects 74.9% of glaucoma cases and correctly classifies 88.8% of those without glaucoma as glaucoma-negative.

The positive likelihood ratio was 3.97 \[95% CI: 2.3--6.7\] while the negative likelihood ratio was 0.21 \[95% CI: 0.14--0.32\] ([Figure 2](#pone-0113779-g002){ref-type="fig"}). This demonstrates that the likelihood of a positive screen test in a glaucoma case is greater than the likelihood of a negative screen test in a non-glaucoma case. In addition, the positive likelihood ratio is greater than one and thus the positive screen test is associated with glaucoma. Since the negative likelihood ratio is less than one, the negative screen test is associated with the absence of disease [@pone.0113779-Trikalinos1]. The effectiveness of the diagnostic accuracy of teleglaucoma was given by the DOR, which was 18.7 \[95% CI: 7.9--44.4\] ([Figure 2](#pone-0113779-g002){ref-type="fig"}). The relative odds of a positive screen test in glaucoma cases are 18.7 times more likely than a negative screen test in a non-glaucoma case. Since the DOR was greater than one the test is discriminating between true positives and true negatives correctly [@pone.0113779-Trikalinos1].

There was insufficient data to conduct hierarchical logistic regression on the percentage of glaucoma diagnosed. Three of the 45 studies reported percentage of glaucoma diagnosed in both teleglaucoma and in-person examination necessary for analysis. The mean percentage of glaucoma diagnosed was 13.4% for teleglaucoma and 7.8% for in-person examination which suggests that teleglaucoma is capable of detecting more cases of glaucoma.

Other effectiveness measures of teleglaucoma were analyzed such as variables of healthcare service quality. The mean percentage of patients referred to specialist for consultation was 12.5±7.8% (n = 6). The mean percentage of images that were of poor quality was 10.4±6.7% (n = 7). It took a mean time of 75.6±87.7 seconds (n = 4) to process the teleglaucoma images. Timing associated with teleglaucoma service is another measure of quality. The mean time for screening was 8.8±5.1 minutes (n = 3). The time reported for ophthalmologist to make diagnosis was 34 minutes (n = 1). The mean reporting time was 7.6±2.6 minutes (n = 6). Teleglaucoma gave a reduction for patient travel time of 61.23 hours (n = 1). Teleglaucoma had a mean access time (time from patient being referred to the date visit is booked) of 59.7±9.9 minutes (n = 4) in comparison to 73.7±29.8 minutes (n = 4) for in-person examination. The mean cycle time (time from registration until patient leaves clinic) for teleglaucoma was 81.7±6 minutes (n = 2), which was less than that of in-person examination, 116±2.5 minutes (n = 2). The mean proportion of patient satisfaction with teleglaucoma was 47.3±8.8% (n = 2) while only 42% (n = 1) were satisfied with in-person examination.

Discussion {#s4}
==========

Telemedicine has demonstrated good use for offering glaucoma services to people of remote areas. Teleglaucoma is beneficial to remote areas as the physician is not required to see patients in person, which reduces wait times and shortens the length of ophthalmic consultations. Teleglaucoma avoids long distance travel and time wasted on commute. The results of the pooled estimates for diagnostic accuracy have shown teleglaucoma to be more sensitive and less specific than in-person examinations. Teleglaucoma is advantageous at detecting true positive cases of glaucoma, but has a higher rate of false positives in comparison to in-person examination. With very high DOR estimates, it is suggested that teleglaucoma can accurately discriminate screen tests. Teleglaucoma has demonstrated capability to detect glaucoma cases that may not have been detected during in-person examination. Glaucoma progresses without patient awareness and it is usually detected at the advanced stages. Thus teleglaucoma serves as a tool for early detection of glaucoma. If caught earlier and with treatment, glaucoma can be effectively managed and can result in the preservation of vision.

Telemedicine for glaucoma can have several combinations of examinations and measurements used for glaucoma screening. Examination of fundus photographs are commonly used for teleglaucoma screening. Four of the ten studies analyzed used only fundus examinations while another four studies included IOP, CCT, visual field loss, and visual acuity, in addition to fundus photograph examinations ([Table 8](#pone-0113779-t008){ref-type="table"}). Two studies did not use fundus photograph examination but rather visual acuity, IOP, CCT, and ACT ([Table 8](#pone-0113779-t008){ref-type="table"}). However, this is based on studies who explicitly stated the terms for ophthalmic examination. Some studies reported "comprehensive eye examinations" were performed, but did not explicitly state which examinations were performed, thus assumptions cannot be made. The use of different tests for glaucoma screening can potentially bias the results as the more diagnostic tools used during screening results in a greater probability of correct diagnosis naturally. However, the results did not show any significant differences in accuracy with studies which reported using multiple diagnostic tools. Interestingly, the specificity and sensitivity values reported ranged independent of the number and the type of examination used for teleglaucoma ([Table 4](#pone-0113779-t004){ref-type="table"} and [Table 8](#pone-0113779-t008){ref-type="table"}).

The combinations of examinations are dependent on financial and resource limitations of the hosting organization and can vary from small programs to very large programs. It is dependent on the target goals and target populations of the organization. However, the standard examinations recommended for glaucoma screening are those that can evaluate visual field defects, IOP, and the biological structure and function of the optic nerve. These include HRT, OCT, optic disc photography, RNFL photography, as well as FDT, tonometry, and perimetry [@pone.0113779-Moyer1]. There were limitations within the study. Insufficient data reported was a major limitation of the meta-analysis, although authors were contacted for additional information. Nevertheless, the key goal was to systematically review the literature on tele-glaucoma and in-person screening and perform the meta-analysis. With small samples sizes there was not enough power to show statistical or clinical significance. Different comparators were reported by studies and to ensure internal validity, only studies with exact comparators were analyzed together. This was one of the reasons for reduced sample sizes for the analysis. However, our analysis does provide information on diagnostic accuracy of teleglaucoma, its capability to detect glaucoma, and to detect negative and positive cases correctly. It demonstrates teleglaucoma has the potential as a screening device to detect a greater amount of cases than in-person examination. Since teleglaucoma is an active screening, it suggests glaucoma cases are detected at earlier stages. However the significance of this difference is limited by the number of comparative studies. The majority of the studies were non-comparative which, in addition, limits the significance of the relative effectiveness to in-person examination.

Teleglaucoma has been evaluated in many different ways: diagnostic accuracy, cost reduction, technological capabilities (image quality, image transmission speed, etc.), reduction of patient and health care provider time, and convenience. Thus many studies focus on only part of the effectiveness. As a result, there is insufficient data when summarizing all of the studies together. This has proven the need for more research literature on the diagnostic accuracy of teleglaucoma and its ability to detect glaucoma in comparison to in-person examination. There is a need for research on the follow-up of detected cases and long-term effects of teleglaucoma. In addition, better quality of evidence through randomized controlled trials is recommended. There are implications for cost-effectiveness analyses. Although, costing data suggests cost savings for patients\' time and travel with teleglaucoma, a thorough costing of current health care expenditure is required to determine its overall cost-effectiveness from the scope of the healthcare system.

Teleglaucoma is beneficial to offering services in underserviced regions and rural areas. It considerably reduces patient access times and cycle times. The time required for service is shorter than in-person examination and physician commitments are reduced. As a result teleglaucoma saves costs to patients and costs to the health care system as a whole.
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